Needham Reiterates Buy on Surmodics, Maintains $36 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Mike Matson reiterates a Buy rating on Surmodics (NASDAQ:SRDX) and maintains a $36 price target.
June 20, 2023 | 2:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson reiterates a Buy rating on Surmodics and maintains a $36 price target.
The reiteration of the Buy rating and maintenance of the $36 price target by Needham analyst Mike Matson indicates a positive outlook for Surmodics. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the confidence of the analyst in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100